fig1
From: Treatment strategy after the discontinuation of immunotherapy for head and neck cancer: a review
Figure 1. Overview of first-line therapy with immune-check point inhibitor and subsequent treatment. Figure created by the author. irAE: Immune-related adverse event, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, psPD: pseudo-progressive disease, HPD: hyper-progressive disease, ICI: immune-checkpoint inhibitor.
